Compare Bank of America Corp (BAC) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of America Corp vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Bank of America Corp trades at $60.74 (market cap $425.43B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B). The key difference: Bank of America Corp is far larger — about 52.9× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bank of America Corp pays a 1.85% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BAC | BIO | |
|---|---|---|
Market Cap | $425.43B | $8.04B |
Volume | 55,637,172 | — |
Sector | Financials | Health |
52-Week High | $60.62 | $339.75 |
52-Week Low | $44.92 | $241.71 |
Dividend Yield | 1.85% | — |
Enterprise Value | — | $7.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of America (BAC) trades at $60.62, up 1.59% today, with a bullish technical signal from moving averages and a consensus analyst price target of $63.79. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.11 exceeding expectations. Revenue grew to $113.10 billion in 2025, and the company maintains a strong deposit franchise, as highlighted by recent news coverage.
The outlook is positive, supported by earnings momentum and potential capital returns post-stress tests. Risks include macroeconomic sensitivity and regulatory changes. Analyst sentiment is strongly bullish, with 65% recommending Buy.
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
